Sally Church has written two pieces about ASCO 2011 that have just been published by Christiane Truelove on the R&D Directions Insider blog.
In her first post entitled “ASCO follow up: Patients, Pathways, Progress in Practice” Sally discusses in detail a clinical study on personalized medicine presented at ASCO by Anatolia Tsimberdou MD, PhD, Associate Professor in the Department of Investigational Cancer Therapeutics at M.D. Anderson Cancer Center in Houston.
In this study, investigators performed molecular analyses on the tumors of 1144 patients with advanced cancer and identified one or more molecular aberrations in 460 (40.2 percent of patients).
Sally notes that “While the study concept is very promising, feasible and logical, there were a number of flaws that may have confounded the interpretation of this ambitious study.” You can read more on Sally’s insightful post on R&D Directions.
In her second guest blog post about ASCO 2011 news, Sally discusses “Molecular Targeted Therapy progress with Lung Cancer.” This is a topic that Sally wrote extensively about in a series of posts on Pharma Strategy Blog recently.
Sally’s guest blog post on R&D Directions discusses in detail the ASCO 2011 presentation by Mark G. Kris MD, chief of the Thoracic Oncology Service and The William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan-Kettering Cancer Center in New York.
Dr Kris presented at ASCO on how the 14- member Lung Cancer Mutation Consortium (LCMC) had identified one of 10 key “driver” mutations that appear in nearly two-thirds of lung cancer patients.
Sally’s conclusion is that:
“After years of treating all lung cancer patients similarly with chemotherapy, we can see at this ASCO meeting that, at least in adenocarcinomas, we are now beginning to make substantial progress not only in delineating the driving mutations, but also mechanisms of acquired resistance to erlotinib and potential new molecular targeted therapies for both ends of the spectrum – that’s good news for patients and oncologists alike.”
You can read more on this topic on Sally’s blog post on R&D Directions.